← Back to Search

Teletherapy Treatments for Anorexia Nervosa

N/A
Recruiting
Led By Ann Haynos, PhD
Research Sponsored by Virginia Commonwealth University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to end of treatment (week 24)
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying how two treatments for Anorexia Nervosa (AN) can help individuals discharged from higher-level care. 80 participants will receive 24 weeks of PAT-AN or PBT therapy through teletherapy. Measures will be taken to assess treatment effectiveness, mental health, and other outcomes.

Who is the study for?
This trial is for adults over 18 with Anorexia Nervosa who are transitioning from intensive treatment to outpatient care or have done so within the last 3 months. They must be willing to participate in weekly assessments, speak English, and have access to a smartphone or computer. Those with medical instability, overlapping therapy content, pregnancy, substance use disorders, or primary psychotic/bipolar-I disorder cannot join.
What is being tested?
The study compares two remote therapies for Anorexia Nervosa after intensive treatment: Positive Affect Treatment (PAT-AN) and Psychoeducational and Behavioral Therapy (PBT). Participants will receive one of these treatments via teletherapy for 24 weeks starting within three months post-discharge.
What are the potential side effects?
Since this trial involves psychological therapies rather than medications, side effects may include emotional discomfort or distress during sessions. However, specific side effects will depend on individual experiences with the therapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to end of treatment (week 24)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to end of treatment (week 24) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Body Mass Index (BMI) from Baseline to End of Treatment
Change in Eating Disorder Symptoms
Secondary study objectives
Change in Anxiety Symptoms
Change in Depressive Symptoms
Change in Suicidal Ideation

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Positive Affect Treatment for Anorexia Nervosa (PAT-AN):Experimental Treatment1 Intervention
Group II: Psychoeducational and Behavioral Therapy (PBT):Active Control1 Intervention

Find a Location

Who is running the clinical trial?

Virginia Commonwealth UniversityLead Sponsor
714 Previous Clinical Trials
22,888,305 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,913 Previous Clinical Trials
2,738,445 Total Patients Enrolled
55 Trials studying Eating Disorders
23,567 Patients Enrolled for Eating Disorders
Ann Haynos, PhDPrincipal InvestigatorPrincipal Investigator
2 Previous Clinical Trials
112 Total Patients Enrolled

Media Library

Positive Affect Treatment for Anorexia Nervosa (PAT-AN) Clinical Trial Eligibility Overview. Trial Name: NCT05799872 — N/A
Eating Disorders Research Study Groups: Positive Affect Treatment for Anorexia Nervosa (PAT-AN):, Psychoeducational and Behavioral Therapy (PBT):
Eating Disorders Clinical Trial 2023: Positive Affect Treatment for Anorexia Nervosa (PAT-AN) Highlights & Side Effects. Trial Name: NCT05799872 — N/A
Positive Affect Treatment for Anorexia Nervosa (PAT-AN) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05799872 — N/A
~35 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top